ArticleIndustrial & engineering chemistry research2018
The Coming Age of Insect Cells for Manufacturing and Development of Protein Therapeutics.
Article in Industrial & engineering chemistry research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Animal Venoms Targeting Cellular Mechanisms: Advances and Implications for Drug Discovery and Disease Therapy.Toxins · 2026Review
- Enhancing CRISPR Homology Directed Repair in IAL-PiD2 Insect Cells via Reagent Delivery Optimization and Cell Synchronization.Biochemical engineering journal · 2026Article
- Thermostable bivalent & trivalent filovirus vaccines from insect cells: potency demonstrated after 3 months and 2 years.Vaccine · 2025Article
- Establishment of Drosophila intestinal cell lines as tools for multiomic screening and deciphering intestinal biology.Scientific reports · 2025Article
- Baculovirus Variant Detection from Transient CRISPR-Cas9-Mediated Disruption ofInternational journal of molecular sciences · 2025Article
- The Bioengineering of Insect Cell Lines for Biotherapeutics and Vaccine Production: An Updated Review.Vaccines · 2025Review
- An insect cell-derived extracellular vesicle-based gB vaccine elicits robust adaptive immune responses against Epstein-Barr virus.Science China. Life sciences · 2025Article
- Modifying Naturally Occurring, Nonmammalian-Sourced Biopolymers for Biomedical Applications.ACS biomaterials science & engineering · 2024Review
- Diverting organic waste from landfills via insect biomanufacturing using engineered black soldier flies (Hermetia illucens).Communications biology · 2024Review
- Probing Baculovirus Vector Gene Essentiality for Foreign Gene Expression Using a CRISPR-Cas9 System.Methods in molecular biology (Clifton, N.J.) · 2024Article
- ADDovenom: Thermostable Protein-Based ADDomer Nanoparticles as New Therapeutics for Snakebite Envenoming.Toxins · 2023Article
- Pseudotyping Improves the Yield of Functional SARS-CoV-2 Virus-like Particles (VLPs) as Tools for Vaccine and Therapeutic Development.International journal of molecular sciences · 2023Article
- Mechanistic modeling explains the production dynamics of recombinant adeno-associated virus with the baculovirus expression vector system.Molecular therapy. Methods & clinical development · 2023Article
- Review
- Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination.NPJ vaccines · 2023Article
- Establishment of a Pseudovirus Platform for Neuraminidase Inhibiting Antibody Analysis.International journal of molecular sciences · 2023Article
- Article
- Article
- Prediction of strain engineerings that amplify recombinant protein secretion through the machine learning approach MaLPHAS.Engineering biology · 2022Article
- Virus-inspired strategies for cancer therapy.Seminars in cancer biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Protein therapeutics is a rapidly growing segment of the pharmaceutical market. Currently, the majority of protein therapeutics are manufactured in mammalian cells for their ability to generate safe and efficacious human-like glycoproteins. The high cost of using mammalian cells for manufacturing has motivated a constant search for alternative host platforms. Insect cells have begun to emerge as a promising candidate, largely due to the development of the baculovirus expression vector system. While there are continuing efforts to improve insect-baculovirus expression for producing protein therapeutics, key limitations including cell lysis and the lack of homogeneous humanized glycosylation still remain. The field has started to see a movement toward virus-less gene expression approaches, notably the use of clustered regularly interspaced short palindromic repeats to address these shortcomings. This review highlights recent technological advances that are realizing the transformative potential of insect cells for the manufacturing and development of protein therapeutics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.